Incyte Corp. buy marge
Start price
18.09.17
/
50%
€107.19
Target price
04.11.21
€135.30
Performance (%)
-45.48%
End price
05.11.21
€58.44
Summary
This prediction ended on 05.11.21 with a price of €58.44. The BUY prediction by marge for Incyte Corp. performed very badly with a performance of -45.48%. marge has a follow-up prediction for Incyte Corp. where he still thinks Incyte Corp. is a Buy. marge has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Incyte Corp. | -3.012% | -3.012% | 40.336% | 13.789% |
| iShares Core DAX® | -4.932% | -11.977% | -3.667% | 45.798% |
| iShares Nasdaq 100 | -2.634% | -2.218% | 14.638% | 78.685% |
| iShares Nikkei 225® | -4.733% | -10.900% | 19.738% | 45.866% |
| iShares S&P 500 | -2.544% | -3.540% | 9.339% | 58.518% |
Comments by marge for this prediction
In the thread Incyte Corp. diskutieren
marge stimmt der Buy-Einschätzung von datca zu: siehe Beschreibung
marge stimmt am 17.11.2016 der Buy-Einschätzung von datca mit dem Kursziel 120$ zu.
Überschrift: Incyte Corporation (INCY),-Kooperationen mit Novartis,Eli Lilly,Merck,MedImmune,Bristol-Myers Squibb,Genentech,Pfizer
In the thread Trading Incyte Corp.
Die von marge gewählte maximale Laufzeit wurde überschritten